Epithelial carcinoma of the ovary: Current strategies

M. E. Katz, P. E. Schwartz, D. S. Kapp, Sharon D Luikart

Research output: Contribution to journalArticlepeer-review

76 Scopus citations

Abstract

Epithelial ovarian cancer is usually diagnosed late in its biologic course (70% of cases are diagnosed as stage III or IV). Recent advances in chemotherapy and radiation therapy offer the possibility of long-term disease-free survival and the potential for cure. The selection of treatment for disease confined to the pelvis (stage I or II) remains controversial. After total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy, high risk patients probably should receive abdominopelvic irradiation or chemotherapy; the relative roles of these two modalities are currently under study. Stage III consists of cases of minimal residual disease at surgery, minimal disease after debulking surgery, and residual large bulky tumor masses. Patients with minimal residual disease are best treated with either abdominopelvic radiation or chemotherapy; patients with stage IV or bulky stage III disease, with chemotherapy. Despite the multiplicity of active single agents, only one study to date has shown a statistically significant improvement in survival for patients with advanced disease utilizing combination chemotherapy.

Original languageEnglish (US)
Pages (from-to)98-111
Number of pages14
JournalAnnals of internal medicine
Volume95
Issue number1
DOIs
StatePublished - Jan 1 1981
Externally publishedYes

Fingerprint Dive into the research topics of 'Epithelial carcinoma of the ovary: Current strategies'. Together they form a unique fingerprint.

Cite this